Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy

Cancer

Volumn 104, Issue 4, 2005, Pages 777-780

  Kantarjian, Hagop M ^a   Bueso Ramos, Carlos E ^a   Talpaz, Moshe ^a   O'Brien, Susan ^a   Giles, Francis ^a   Faderl, Stefan ^a   Wierda, William ^a   Rios, Mary Beth ^a   Shan, Jianqin ^a   Cortes, Jorge ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chronic myelogenous leukemia; Imatinib mesylate; Myelofibrosis; Philadelphia chromosome; Positive chronic phase; Prognostic significance

Indexed keywords

BCR ABL PROTEIN; IMATINIB; RETICULIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MYELOFIBROSIS; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; MYELOFIBROSIS; PIPERAZINES; PROGNOSIS; PYRIMIDINES; SURVIVAL ANALYSIS;

EID: 23444445468     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21235     Document Type: Article

References (21)

1. Garcia-Manero G, Faderl S, O'Brien S, Cortes J, Talpaz M, Kantarjian H. Chronic myelogenous leukemia: a review and update of therapeutic strategies. Cancer. 2003;98:437-457.
2. Goldman J, Melo J. Chronic myeloid leukemia - advances in biology and new approaches to treatment. N Engl J Med. 2003;349:1451-1464.
3. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase myeloid leukemia. N Engl J Med. 2003; 348:994-1004.
4. Kantarjian H, Cortes J, O'Brien S, et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood. 2003;101:97-100.
5. Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. 2004;103:2873-2878.
6. Hughes T, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423-1432.
7. Cortes J, Talpaz M, O'Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res. 2005; 11:3425-3432.
8. Guilhot F. Sustained durability of responses plus high rates of cytogenetic responses result in long-term benefit for newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) treated with imatinib (IM) therapy: update from the IRIS study [abstract]. Blood. 2004;11:10a.
9. Branford S, Rudzki Z, Grigg A, et al. Bcr-Abl levels continue to decrease up to 42 months after commencement of standard dose imatinib in patients with newly diagnosed chronic phase CML who achieve a major molecular response [abstract]. Blood. 2004;11:82a.
10. Anstrom K, Reed S, Glendenning G, Foster J, Hensley M, Schulman K for the IRIS Study Team. Estimated long-term survival benefit of imatinib therapy in patients with newly diagnosed chronic myeloid leukemia [abstract]. J Clin Oncol (Suppl). 2003;22:589.
11. Cortes J, Talpaz M, O'Brien S, et al. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 2003;98:1105-1113.
12. Dekmezian R, Kantarjian H, Keating M, Talpaz M, McCredie KB, Freireich EJ. The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia. Cancer. 1987;59:1739-1743.
13. Kvasnicka HM, Thiele J, Schmitt-Graeff A, et al. Bone marrow features improve prognostic efficiency in multivariate risk classification of chronic-phase Ph(1+) chronic myelogenous leukemia: a multicenter trial. J Clin Oncol. 2001;19:2994-3009.
14. Buesche G, Hehlmann R, Hecker H, et al. A. Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trial. Leukemia. 2003;17:2444-2453.
15. Wilhelm M, Bueso-Ramos C, O'Brien S, et al. Effect of interferon-alpha therapy on bone marrow fibrosis in chronic myelogenous leukemia. Leukemia. 1998;12:65-70.
16. Thiele J, Kvasnicka HM, Schmitt-Graeff A, et al. Effects of interferon and hydroxyurea on bone marrow fibrosis in chronic myelogenous leukaemia: a comparative retrospective multicenter histological and clinical study. Br J Haematol. 2000;108:64-71.
17. Kaban K, Kantarjian H, Talpaz M, et al. Expression of thrombopoietin and its receptor (c-mpl) in chronic myelogenous leukemia: correlation with disease progression and response to therapy. Cancer. 2000;88:570-576.
18. Wetzler M, Kurzrock R, Lowe DG, Kantarjian H, Gutterman JU, Talpaz M. Alteration in bone marrow adherent layer growth factor expression: a novel mechanism of chronic myelogenous leukemia progression. Blood. 1991;78:2400-2406.
19. Bueso-Ramos CE, Cortes J, Talpaz M, et al. Imatinib mesylate therapy reduces bone marrow fibrosis in chronic myelogenous leukemia. Cancer. 2004;101:332-336.
20. Beham-Schmid C, Apfelbeck U, Sill H, et al. Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood. 2002;99:381-383.
21. Hasserjian P, Boecklin F, Parker S, et al. STI571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response. Am J Clin Pathol. 2002;117:360-367.